Hepatitis Clinical Trials

Showing 501-520 of 1,819 trials

A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection

NCT05542979

This is a multicenter, randomized, double-blind, placebo-controlled, multiple-ascending dose phase Ib study of HH-003 injection, which is a monoclonal antibody targeting Hepatitis B virus. This study aims to evaluate the safety, tolerability and pharmacokinetics of HH-003 injection in treatment-naive participants chronically infected with hepatitis B virus.

Chronic HBV Infection

Huahui Health68 participantsStarted Aug 2019

Beijing, Beijing Municipality, China • Beijing, Beijing Municipality, China • Beijing, Beijing Municipality, China +8 more locations

TERMINATEDPhase 2

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT03551522

A Phase 2, Double-Blind (DB), Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH) OLE phase was not analyzed due to the early termination of the study

NASH - Nonalcoholic Steatohepatitis

Gilead Sciences181 participantsStarted Apr 2018

Glendale, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +11 more locations

A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Related Searches

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients

Intrafamilial Transmission of Hepatitis B Virus: Frequency, Risk Factors, and Role of Hepatitis B Vaccination

Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD

The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years

Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy

A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid

Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients

Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)